Shares of Per-Se Technologies ( PSTI - Get Report) were among the worst-performing health-related stocks Tuesday, sliding 8% after the company posted weaker-than-expected fourth-quarter results.

The company, which provides management services to physicians and hospitals, earned $11.9 million, or 34 cents a share. Excluding a tax benefit, the company earned $9.3 million, or 27 cents a share. Analysts polled by Thomson First Call expected earnings of 29 cents a share, before items. Per-Se recorded sales of $93.4 million, shy of analysts' mean estimate of $95.4 million. During the year-earlier period, the company earned $36 million, or $1.11 a share, on sales of $89.4 million. Excluding items, the company earned $7.7 million, or 24 cents a share, during a year earlier.

Per-Se Technologies now sees 2006 earnings, excluding items, of $1.30 to $1.40 a share. Previously, the company predicted earnings of $1.28 to $1.38 a share. The company predicts sales of $625 million to $635 million. Analysts project earnings of $1.39 a share and sales of $525.5 million. Shares were trading down $2.03 to $22.94.

LifeCell ( LIFC) fell 9% after the company posted in-line fourth-quarter earnings. The company, which develops products made from human tissue for use in surgical procedures, earned $3.8 million, or 11 cents a share, on revenue of $27.3 million. Analysts expected earnings of 11 cents a share and revenue of $26.8 million. During the year-earlier period, the company earned $4.1 million, or 13 cents a share, on revenue of $16.7 million. Excluding a tax benefit, the company earned $1.3 million, or 4 cents a share, a year earlier.

Looking ahead, LifeCell sees 2006 earnings, excluding stock-based compensation costs, of 59 cents to 63 cents a share. The company predicts product revenue of $124 million to $130 million. Analysts project earnings, excluding stock-based compensation costs, of 62 cents a share. LifeCell shares were down $2.08 to $21.85.

Shares of Noven Pharmaceuticals ( NOVN - Get Report) rose 2% after the maker of drug skin patches posted better-than-expected fourth-quarter results. The company earned $6.1 million, or 25 cents a share, for the fourth quarter. Excluding items, the company earned $2.7 million, or 11 cents a share, beating analysts' mean estimate by a penny. Revenue totaled $16.8 million, compared with Wall Street's estimate of $11.5 million. During the year-earlier period, the company earned $2.8 million, or 11 cents a share, on revenue of $12.7 million. Shares traded up 28 cents to $15.17.

Genta ( GNTA) fell 9% after the biopharmaceutical company laid out plans to sell some 19 million shares of stock to institutional investors for gross proceeds of about $40.8 million. The sale, which is being done as a registered direct offering, is expected to close on March 10. Shares were trading down 21 cents to $2.22.

Shares of Decode Genetics ( DCGN) fell 6% after the biotech company posted fourth-quarter results that were below expectations. The company reported a loss of $21.1 million, or 39 cents a share, on revenue of $9.8 million. Analysts expected a loss of 30 cents a share and revenue of $11.5 million. The company's year-earlier loss totaled $19.4 million, or 36 cents a share, on revenue of $11.2 million. Shares were trading down 56 cents to $8.87.

Other health care volume movers included Pfizer ( PFE - Get Report), down 9 cents to $25.89; Generex Biotech ( GNBT), down 16 cents to $2.08; Boston Scientific ( BSX - Get Report), down 10 cents to $23.50; Schering-Plough ( SGP), down 15 cents to $17.97; Johnson & Johnson ( JNJ), up 27 cents to $58.12; Novavax ( NVAX), down 23 cents to $5.54; Amgen ( AMGN), up 1 cent to $73.56; Merck ( MRK), down 12 cents to $34.84; and Bristol-Myers Squibb ( BMY), down 21 cents to $22.60.